Ralph DeBerardinis was born, raised, and educated in the Philadelphia area, earning a B.S. in Biology from St. Joseph’s University (summa cum laude) in 1992, and M.D. and Ph.D. degrees from the University of Pennsylvania. For his thesis work with Dr. Haig H. Kazazian at Penn, Dr. DeBerardinis studied L1 retrotransposons in the mouse and human genomes and determined several aspects of their impact on genome fluidity and evolution.
After finishing his M.D./Ph.D. training, Dr. DeBerardinis stayed in Philadelphia to become the first trainee in the combined residency program in Pediatrics and Medical Genetics at The Children’s Hospital of Philadelphia (CHOP), receiving several awards for teaching and clinical care and ultimately achieving board certification in Pediatrics, Medical Genetics, and Clinical Biochemical Genetics. Dr. DeBerardinis served as an attending physician for two years in the Section of Biochemical Genetics at CHOP.
Dr. DeBerardinis performed postdoctoral research training in the laboratory of Craig B. Thompson, M.D., in the Penn Cancer Center from 2004-2007, where he explored the connections between cellular signal transduction and core metabolic pathways in proliferating cells. These studies led to several novel observations connecting growth factor signaling with specific metabolic activities, including glycolysis, glutaminolysis, the Krebs cycle and the synthesis and degradation of fatty acids. These observations raised the possibility that different oncogenic signaling pathways regulate distinct aspects of cellular metabolism, arguing for metabolic synergy among the mutations that cause cancer.
In 2008, Dr. DeBerardinis moved to Dallas to join the faculty of the University of Texas Southwestern Medical Center as an Assistant Professor of Pediatrics and Genetics. His lab continues to focus on integrating cellular signal transduction and metabolism during both normal cell proliferation and tumorigenesis. He is also an attending physician in the Division of Pediatric Genetics and Metabolism at Children’s Medical Center, where he is involved in the diagnosis and care of children with inborn errors of metabolism.
- Medical School
- University of Pennsylvania School of Medicine (2000)
- Children's Hospital of Philadelphia (2005), Pediatrics & Medical Genetics
- Mitochondrial Disorders
- Newborn Screening
- Genetic disorders in children
- Inborn errors of metabolism
- Reductive carboxylation supports growth in tumour cells with defective mitochondria.
- Mullen AR, Wheaton WW, Jin ES, Chen PH, Sullivan LB, Cheng T, Yang Y, Linehan WM, Chandel NS, Deberardinis RJ Nature 2011 Nov
- Pyruvate carboxylase is required for glutamine-independent growth of tumor cells.
- Cheng T, Sudderth J, Yang C, Mullen AR, Jin ES, Matés JM, DeBerardinis RJ Proc. Natl. Acad. Sci. U.S.A. 2011 May 108 21 8674-9
- Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling.
- Yang C, Sudderth J, Dang T, Bachoo RM, Bachoo RG, McDonald JG, DeBerardinis RJ Cancer Res. 2009 Oct 69 20 7986-93
- The biology of cancer: metabolic reprogramming fuels cell growth and proliferation.
- DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB Cell Metab. 2008 Jan 7 1 11-20
- Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis.
- DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, Thompson CB Proc. Natl. Acad. Sci. U.S.A. 2007 Dec 104 49 19345-50
- The Proto-oncometabolite Fumarate Binds Glutathione to Amplify ROS-Dependent Signaling.
- Sullivan LB, Garcia-Martinez E, Nguyen H, Mullen AR, Dufour E, Sudarshan S, Licht JD, Deberardinis RJ, Chandel NS Mol. Cell 2013 Jun
- Cancer. Silencing a metabolic oncogene.
- Kim J, DeBerardinis RJ Science 2013 May 340 6132 558-9
- A comparative study of short- and long-TE (1) H MRS at 3 T for in vivo detection of 2-hydroxyglutarate in brain tumors.
- Choi C, Ganji S, Hulsey K, Madan A, Kovacs Z, Dimitrov I, Zhang S, Pichumani K, Mendelsohn D, Mickey B, Malloy C, Bachoo R, Deberardinis R, Maher E NMR Biomed 2013 Apr
- AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo.
- Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z, Dupuy F, Chambers C, Fuerth BJ, Viollet B, Mamer OA, Avizonis D, DeBerardinis RJ, Siegel PM, Jones RG Cell Metab. 2013 Jan 17 1 113-24
- Mitochondrial reactive oxygen species promote epidermal differentiation and hair follicle development.
- Hamanaka RB, Glasauer A, Hoover P, Yang S, Blatt H, Mullen AR, Getsios S, Gottardi CJ, Deberardinis RJ, Lavker RM, Chandel NS Sci Signal 2013 6 261 ra8
Honors & Awards
- Damon Runyon Cancer Research Foundation Clinical Investigator Award
- President’s Research Council Distinguished Young Researcher Award
- Soc. for Inherited Metabolic Disorders Neil Buist Award
- Sowell Family Scholar in Medical Research
- William K. Bowes, Jr. Award in Medical Genetics
- CHOP Pediatric Scholars Program & Faculty Honor Roll
- American Society for Clinical Investigation
- American Society for Clinical Investigation (2013)
- American Academy of Pediatrics
- American Association for Cancer Research
- American Society of Human Genetics
- Society for Inherited Metabolic Disorders
- Society for Pediatrics Research